Caring Ambassadors Program

Hepatitis C Newsletter

August 2011


Clinical Trials, Cohort Studies, Pilot Studies


Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. Patel K, Thompson AJ, Chuang WL, et al. J Gastroenterol Hepatol. 2011 Jul;26(7):1182-1188. doi: 10.1111/j.1440-1746.2011.06722.x.


A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. Lan CL, Guillygomarc'h A, Danielou H, et al. J Hepatol. 2011 Jul 11. [Epub ahead of print]

Maladies du Foie, F-35033 Rennes, France; INSERM, UMR-991, F-35000, France.


Hyporesponsiveness to pegifnα2b plus ribavirin in patients with hepatitis C-related advanced fibrosis. Prati GM, Aghemo A, Rumi MG, et al. J Hepatol. 2011 Jul 11. [Epub ahead of print]


A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. Evon DM, Simpson K, Kixmiller S, et al. Am J Gastroenterol. 2011 Jul 19. doi: 10.1038/ajg.2011.219. [Epub ahead of print]


Improved Responses to Pegylated Interferon alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. Sarrazin C, Schwendy S, Möller B, et al. Gastroenterology. 2011 Jul 21. [Epub ahead of print]


Association of laboratory parameters with viral factors in patients with hepatitis C. Ijaz B, Ahmad W, Javed FT, et al. Virol J. 2011 Jul 21;8(1):361. [Epub ahead of print]


Mallory-Denk Bodies are Associated with Outcomes and Histologic Features in Patients with Chronic Hepatitis C. Rakoski MO, Brown MB, Fontana RJ, et al. Clin Gastroenterol Hepatol. 2011 Jul 20. [Epub ahead of print]


IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. Chayama K, Hayes CN, Abe H, et al. J Infect Dis. 2011 Jul;204(1):84-93.


Basic and Applied Science, Pre-Clinical Studies


Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, Yokosuka O. Scand J Gastroenterol. 2011 Jul;46(7-8):955-61.


Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Foster TL, Verow M, Wozniak AL, et al. Hepatology. 2011 Jul;54(1):79-90. doi: 10.1002/hep.24371.


Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Rowell J, Thompson AJ, Guyton JR, et al. Hepatol Int. 2011 Jul 7. [Epub ahead of print]


Mechanistic characterization of gs-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis c virus ns5b polymerase. Shih IH, Vliegen I, Peng B,  et al. Antimicrob Agents Chemother. 2011 Jul 11. [Epub ahead of print]


Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. Fraser J, Boo I, Poumbourios P, Drummer HE. J Biol Chem. 2011 Jul 15. [Epub ahead of print]


Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response. Estrabaud E, De Muynck S, Asselah T. J Hepatol. 2011 Jul 1. [Epub ahead of print]


Characterization of Serum Proteins Associated with IL28B Genotype among Patients with Chronic Hepatitis C. Cyr DD, Lucas JE, Thompson JW, et al. PLoS One. 2011;6(7):e21854. Epub 2011 Jul 5.


The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection. Ackerman Z, Pappo O, Ben-Dov IZ. J Med Virol. 2011 Jul;83(7):1262-8. doi: 10.1002/jmv.22093.


Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. Liang CC, Liu CH, Lin YL, Liu CJ, Chiang BL, Kao JH. J Med Virol. 2011 Jul;83(7):1212-20. doi: 10.1002/jmv.22096.


High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-{gamma} Antonelli A, Ferri C, Ferrari SM, et al. J Rheumatol. 2011 Jul 1. [Epub ahead of print]


HIV/HCV/HBV Coinfection


Interference of replication between hepatitis B and C viruses in patients infected with HIV.

Yang RR, Gui X, Chen XY, Zhu Y. J Med Virol. 2011 Jul;83(7):1159-64. doi: 10.1002/jmv.22102.


Treatment of acute hepatitis C infection in HIV-infected patients. Boesecke C, Rockstroh JK. Curr Opin HIV AIDS. 2011 Jul;6(4):278-84.


Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis. Ingiliz P, Valantin MA, Petrosi P, et al. J Hepatol. 2011 Jul 19. [Epub ahead of print]


IL28B Polymorphism Associated with Spontaneous Clearance of Hepatitis C Infection in a Southern Brazilian HIV Type 1 Population. Lunge VR, da Rocha DB, Béria JU, Tietzmann DC, Stein AT, Simon D. AIDS Res Hum Retroviruses. 2011 Jul 26. [Epub ahead of print]


An overview of Triple infection with Hepatitis B, C and D viruses. Riaz M, Idrees M, Kanwal H, Kabir F. Virol J. 2011 Jul 27;8(1):368. [Epub ahead of print]


Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. Pineda JA, Caruz A, Di Lello FA, et al. AIDS. 2011 Jul 17;25(11):1415-20.


Complementary and Alternative Medicine


Vitamin-D: An innate antiviral agent suppressing Hepatitis C virus in human hepatocytes.

Gal-Tanamy M, Bachmetov L, Ravid A, et al. Hepatology. 2011 Jul 25. doi: 10.1002/hep.24575. [Epub ahead of print]

Glycyrrhizin as antiviral agent against Hepatitis C Virus. Ashfaq UA, Masoud MS, Nawaz Z, Riazuddin S. J Transl Med. 2011 Jul 18;9(1):112. [Epub ahead of print]


Epidemiology, Diagnostics, and Miscellaneous Works


An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. O'Brien TR, Everhart JE, Morgan TR, et al. PLoS One. 2011;6(7):e20904. Epub 2011 Jul 8.


Comparison of 9 blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. Zarski JP, Sturm N, Guechot J, Paris A, et al. J Hepatol. 2011 Jul 19. [Epub ahead of print]


Infections and the liver. Eksteen B. Dig Dis. 2011;29(2):184-90. Epub 2011 Jul 5.


Racial differences in hepatitis C treatment eligibility. Melia MT, Muir AJ, McCone J, et al. Hepatology. 2011 Jul;54(1):70-78. doi: 10.1002/hep.24358.


Acute hepatitis C in Korea: different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion. Kim JY, Won JE, Jeong SH, et al. J Med Virol. 2011 Jul;83(7):1195-202. doi: 10.1002/jmv.22100.


A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.

Sievert W, Altraif I, Razavi HA, et al. Liver Int. 2011 Jul;31 Suppl 2:61-80. doi: 10.1111/j.1478-3231.2011.02540.x.


A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.

Cornberg M, Razavi HA, Alberti A, et al. Liver Int. 2011 Jul;31 Suppl 2:30-60. doi: 10.1111/j.1478-3231.2011.02539.x.


Trends and projections of hepatitis C virus epidemiology in Latin America. Kershenobich D, Razavi HA, Sánchez-Avila JF, et al. Liver Int. 2011 Jul;31 Suppl 2:18-29. doi: 10.1111/j.1478-3231.2011.02538.x.


A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Hagan H, Pouget ER, Des Jarlais DC. J Infect Dis. 2011 Jul;204(1):74-83.

Unmet needs among people reported with hepatitis C, New York City. Bornschlegel K, Crotty KJ, Sahl S, Balter S. J Public Health Manag Pract. 2011 Jul-Aug;17(4):E9-17.


The increasing mortality burden of liver disease among opioid dependent people: Cohort study. Gibson A, Randall D, Degenhardt L. Addiction. 2011 Jul 12. doi: 10.1111/j.1360-0443.2011.03575.x. [Epub ahead of print]


Gaps in the Achievement of Effectiveness of HCV Treatment in National VA Practice.

Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag H, Kramerer JR. J Hepatol. 2011 Jul 11. [Epub ahead of print]


Liver Cancer


Liver cancer and non-hodgkin lymphoma in hepatitis C virus-infected patients: results from the danvir cohort study. Omland LH, Jepsen P, Krarup H, et al. Int J Cancer. 2011 Jul 21. doi: 10.1002/ijc.26283. [Epub ahead of print]


Peginterferon Maintenance Therapy in Patients with Advanced Hepatitis C to Prevent Hepatocellular Carcinoma: The Plot Thickens. Aghemo A, Colombo M. J Hepatol. 2011 Jul 20. [Epub ahead of print]